Stock listing

OTC:CASIF CASI Pharmaceuticals, Inc. Stock

Follow CASI Pharmaceuticals, Inc. into a list and get an email when it puts out news.

Share price · OTC:CASIF

$0.10 USD +0.00 (+0.1%)

Close on Nov 20, 2026

Past year -91.6% · daily closes, Nov 20, 2025 – Nov 20, 2026, adjusted for splits
Day range
$0.10 – $0.10 USDNov 20, 2026
Volume
15,012 sharesNov 20, 2026
Market cap
$2.06M USDAt the close on Nov 20, 2026 · price × 20.56M shares outstanding
52-week range
$0.05 – $1.25 USDLowest and highest trades, Nov 21, 2025 – Nov 20, 2026
Traded on an average day
$223 USDMedian day 700 shares · 6 days with no trades · last 3 months, Aug 20, 2026 – Nov 20, 2026
CASI Pharmaceuticals, Inc. logo

Daily closes

Last 3 months, Aug 20, 2026 – Nov 20, 2026 · OTC:CASIF · USD, adjusted for splits

DayCloseChange%OpenHighLowVolume
$0.10+0.00+0.1%$0.10$0.10$0.1015,012
$0.100.000.0%$0.10$0.10$0.1070
$0.100.000.0%$0.10$0.10$0.1010,000
$0.100.000.0%$0.10$0.10$0.102
$0.100.000.0%$0.10$0.10$0.101,575
$0.100.000.0%$0.10$0.10$0.10887
$0.100.00-0.1%$0.10$0.10$0.1018,434
$0.10-0.01-9.0%$0.10$0.10$0.10726
$0.11+0.01+9.9%$0.11$0.11$0.11709
$0.10+0.00+0.1%$0.10$0.10$0.1050
$0.100.000.0%$0.10$0.10$0.10189
$0.10-0.015-12.9%$0.105$0.105$0.10145
$0.115-0.015-11.8%$0.133$0.133$0.1154,892
$0.13+0.013+10.7%$0.13$0.13$0.13258
$0.118+0.017+17.5%$0.11$0.118$0.11356
$0.100.000.0%$0.10$0.10$0.10252
$0.100.000.0%$0.10$0.10$0.10625
$0.100.000.0%$0.12$0.12$0.104,100
$0.100.000.0%$0.10$0.10$0.105,200
$0.100.000.0%$0.10$0.10$0.10900
$0.100.000.0%$0.10$0.10$0.10500
$0.100.000.0%$0.10$0.10$0.10700
$0.100.000.0%$0.10$0.10$0.10400
$0.100.000.0%$0.10$0.10$0.10700
$0.100.000.0%$0.10$0.10$0.10300
$0.10-0.01-9.1%$0.11$0.11$0.102,300
$0.110.000.0%$0.11$0.11$0.112,100
$0.110.000.0%$0.11$0.11$0.11200
$0.110.000.0%$0.11$0.13$0.114,500
$0.110.000.0%$0.11$0.11$0.113,000
$0.110.000.0%$0.11$0.11$0.11800
$0.11-0.01-8.3%$0.11$0.11$0.11200
$0.120.000.0%$0.12$0.12$0.121,000
$0.12+0.01+9.1%$0.11$0.12$0.113,300
$0.110.000.0%$0.11$0.11$0.1150
$0.11-0.01-8.3%$0.11$0.11$0.11300
$0.12-0.01-7.7%$0.13$0.13$0.121,300
$0.13-0.03-18.8%$0.13$0.13$0.13600
$0.160.000.0%$0.16$0.16$0.160
$0.16+0.03+23.1%$0.13$0.16$0.132,800
$0.130.000.0%$0.13$0.13$0.13300
$0.130.000.0%$0.13$0.13$0.13700
$0.13-0.01-7.1%$0.13$0.14$0.13400
$0.14+0.01+7.7%$0.13$0.14$0.131,700
$0.130.000.0%$0.13$0.13$0.130
$0.130.000.0%$0.13$0.13$0.1358
$0.13-0.01-7.1%$0.13$0.14$0.132,500
$0.140.000.0%$0.14$0.14$0.140
$0.14+0.01+7.7%$0.14$0.14$0.143,000
$0.13-0.01-7.1%$0.14$0.14$0.136,300
$0.14-0.01-6.7%$0.14$0.14$0.1412,200
$0.150.000.0%$0.15$0.15$0.15700
$0.15+0.01+7.1%$0.15$0.15$0.15700
$0.14+0.01+7.7%$0.14$0.14$0.141,500
$0.130.000.0%$0.13$0.13$0.130
$0.130.000.0%$0.13$0.13$0.13100
$0.13-0.01-7.1%$0.13$0.13$0.131,700
$0.14+0.01+7.7%$0.14$0.14$0.14100
$0.130.000.0%$0.13$0.13$0.130
$0.13-0.01-7.1%$0.13$0.13$0.13100
$0.14+0.01+7.7%$0.13$0.14$0.13500
$0.130.000.0%$0.13$0.13$0.130
$0.130.000.0%$0.13$0.13$0.131,200

Splits

2 splits since 2010 · OTC:CASIF · every price before a split is adjusted for it

DayRatioWhat
1-for-10Consolidation
1-for-11Consolidation
Ticker
OTC:CASIF
Asset type
Stock
Sector
Health care
Industry
Biotechnology
Exchange
OTC
Currency
USD

What changed lately

CASI Pharmaceuticals, Inc. on 6ix

Sector
Health care
Industry
Biotechnology
Calls
1 call with a replay · 1 with a transcript · latest Mar 12, 2021
Decks
22 decks · latest January 2026

Valuation

EV/sales 1.9× against a median of −11.6×: the highest of 4 Biotechnology companies shown. Statements: 4 quarters to Jun 30, 2026 · price Nov 20, 2026

Enterprise value
$38.79M USD
P/E
Loss
EV/sales
1.9×
EV/EBITDA
No depreciation figure on 6ix yet
Price/book
Negative equity
Gross margin
60.0%
Operating margin
−191.0%
Net margin
−218.6%
Debt to equity
Negative equity
Beta vs S&P 500
-0.07

Biotechnology: the 10 companies nearest in size, of 890 on 6ix with figures. Size in US dollars.

CompanyMkt capEVP/EEV/SalesEV/EBITDAP/BNet mgnDebt/EqBeta
CASI Pharmaceuticals, Inc. · OTC:CASIFUS$2.06MUS$38.79Mn/a1.9×n/an/a−218.6%n/a-0.07
Ernexa Therapeutics Inc. · NASDAQ:ERNAUS$2.30M−US$2.96Mn/an/an/a0.5×n/a0.1×0.86
Cynata Therapeutics Limited · ASX:CYPUS$2.26MUS$1.66Mn/a1.5×n/an/a−540.4%n/an/a
PharmaCyte Biotech, Inc. · NASDAQ:PMCBUS$2.25M−US$15.59Mn/an/an/a0.1×n/a0.0×1.97
Modus Therapeutics Holding AB · OMXSTO:MODTXUS$2.22MUS$1.00Mn/an/an/a2.2×n/a0.0×n/a
Nuformix PLC · LSE:NFXUS$2.22MUS$1.00Mn/an/an/a1.0×n/a0.0×n/a
Medicus Pharma Ltd. · NASDAQ:MDCXUS$2.18M−US$2.73Mn/an/an/an/an/an/a2.03
Senti Biosciences Holdings, Inc. · NASDAQ:SNTIUS$2.06M−US$3.49Mn/a−47.2×n/an/an/an/a2.91
Vectus Biosystems Limited · ASX:VBSUS$2.02MUS$50,9461.9×n/an/a1.3×n/a0.2×n/a
Decoy Therapeutics Inc. · NASDAQ:DCOYUS$1.98M−US$6.19Mn/a−11.6×n/a0.4×n/a0.0×1.28
Genprex, Inc. · NASDAQ:GNPXUS$1.94M−US$13.41Mn/an/an/a0.1×n/a0.0×1.08
Median of the othersUS$2.20M−US$2.85M1.9×−11.6×0.5×−540.4%0.0×1.63

Forecasts

Analysts' consensus from EODHD, read Nov 18, 2026. Not 6ix's view and not investment advice.

Price target
4.00 USD · Analysts' mean
EPS, year to Dec 2026
-1.41 · 1 analyst

Team and board

Officers

OfficerRole
Chunhua WangChief Operating Officer
Wei GaoGeneral Counsel
Junping ChenChief Medical Officer
Kun QianGlobal Controller
Wei-Wu HeExecutive Chairman

Board

DirectorRole
Wei-Wu HeExecutive Chairman
Alex WuDirector
Frank SuDirector
James HuangDirector
Thomas FolinsbeeDirector
Xuebo ZengDirector

Events

Calls

CallWhenStatus
CASI Pharmaceuticals (OTC:CASIF) Q4 2020 Earnings CallFri, Mar 12, 2021 · 8:00 AM ETReplay

Results days

QuarterResultsShare move
Q1 2026May 15, 2026 · Before open+7.1%
Q3 2025Nov 14, 2025 · After close−5.6%
Q2 2025Aug 29, 2025 · After close−0.4%
Q1 2025May 16, 2025 · Before open+7.2%
Q3 2024Nov 15, 2024 · Before open−9.3%
Q2 2024Aug 16, 2024 · Before open0.0%
Q1 2024May 14, 2024+27.2%
Q4 2023Mar 28, 2024 · Before open+20.3%
Q3 2023Nov 14, 2023 · Before open+1.1%
Q2 2023Aug 11, 2023 · Before open+3.6%
All 19 quarters
QuarterResultsShare move
Q1 2023May 17, 2023 · Before open−7.6%
Q3 2022Nov 14, 2022 · Before open−4.5%
Q2 2022Aug 12, 2022 · Before open−10.8%
Q1 2022May 12, 2022 · Before open−6.1%
Q4 2021Mar 28, 2022+9.4%
Q3 2021Nov 12, 2021 · Before open+2.9%
Q2 2021Aug 12, 2021 · Before open−1.7%
Quarter to Mar 31, 2021May 13, 2021 · Before open−2.1%
Quarter to Dec 31, 2020Mar 30, 2021+21.2%

Open Events

Decks

DeckKindSlidesDate
Investor Presentation (January 2026)Investor deck28 slidesJanuary 2026
Corporate Update (May 2025)Corporate update21 slidesMay 21, 2025
Investor Presentation (August 2022)Investor deck30 slidesAugust 2022
Investor Presentation (May 2022)Investor deck30 slidesMay 2022
Jefferies London Healthcare Conference 2021Conference29 slidesNovember 2021
Investor Presentation (September 2021)Investor deck21 slidesSeptember 2021
Investor Presentation (September 2021)Investor deck24 slidesSeptember 2021
Investor Presentation (August 2021)Investor deck37 slidesAugust 2021
Shareholder Meeting (June 2021)Shareholder meeting37 slidesJun 15, 2021
Investor Presentation (March 2021)Investor deck12 slidesMar 12, 2021
All 22 decks
DeckKindSlidesDate
HCW 22nd Annual Global Investment Conference (September 2020)Conference26 slidesSep 14, 2020
Investor Presentation (June 2020)Investor deck20 slidesJune 2020
Investor Presentation (September 2019)Investor deck13 slidesSeptember 2019
BIO International 2019Conference20 slidesJul 14, 2019
Shareholder Meeting (June 2018)Shareholder meeting21 slidesJun 11, 2018
Investor Presentation (June 2018)Investor deck13 slidesJun 4, 2018
BIO CEO & Investor Conference 2018Conference18 slidesFeb 13, 2018
Investor Presentation (October 2017)Investor deck17 slidesOctober 2017
Rodman & Renshaw 19th Annual Global Investment Conference (September 2017)Conference23 slidesSep 11, 2017
Shareholder Meeting (June 2017)Shareholder meeting35 slidesJun 8, 2017
Investor Presentation (November 2014)Investor deck48 slidesNov 17, 2014
Investor Presentation (May 2014)Investor deck7 slidesMay 2014

Open Decks

Financials

Annual, in USD

Income statement

LineFY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016
Revenue20.7M28.5M33.9M43.1M30.2M15.1M4.13M
Cost of revenue10.6M17.4M13.8M15.8M12.6M9.51M3.94M1.67M117.8K66.5K
Gross profit10.1M11.1M20.1M27.3M17.6M5.63M196.0K-1.67M-117.8K-66.5K
Research and development6.31M8.92M9.86M16.0M14.4M11.5M9.75M8.51M7.60M4.65M
Selling, general and administrative46.6M23.6M25.4M23.4M23.7M19.7M27.3M18.0M3.16M4.78M
Operating income-45.0M-39.6M-25.1M-34.0M-41.5M-52.8M-40.0M-26.5M-10.8M9.42M
Depreciation and amortization1.20M1.30M2.50M1.20M500.0K600.0K2.15M1.67M117.8K66.5K
EBITDA-43.8M-38.3M-22.6M-32.8M-41.0M-52.2M-37.8M-24.8M-10.6M9.49M
Interest expense840.0K871.0K15.0K02.90K3.10K8.21K15.0K33.8K
Income before tax-45.9M-38.1M-26.3M-37.4M-35.8M-47.5M-45.4M-27.5M-10.8M-9.45M
Income tax0-81.0K1.98M0015.0K33.8K
Net income-48.1M-39.3M-27.0M-41.0M-36.7M-48.3M-45.4M-27.5M-10.8M-9.45M
Earnings per share, basic-2.59-2.56-2.02-3.01-2.69-4.37-4.73-3.24-1.75-1.69
Earnings per share, diluted-2.59-2.56-2.02-3.01-2.69-4.37

Balance sheet

LineFY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016
Cash and equivalents5.63M13.5M17.1M47.1M38.7M57.1M53.6M84.2M43.5M27.1M
Short-term investments02.62M12.0M1.46M9.87M9.31M625.0K912.2K
Receivables4.09M15.3M9.55M13.0M9.80M4.64M1.29M
Inventory1.60M5.25M15.9M6.14M1.91M1.36M4.54M283.0K
Current assets13.5M39.6M59.3M73.4M62.0M74.0M61.5M92.6M43.8M27.4M
Property, plant and equipment6.97M7.87M9.24M11.8M12.7M
Total assets25.6M53.7M75.3M96.2M138.3M127.7M102.6M113.4M45.1M27.7M
Accounts payable1.06M2.72M4.44M3.29M2.22M3.26M5.11M968.0K2.09M1.06M
Current liabilities49.7M36.5M16.7M17.0M13.2M7.98M7.95M3.87M5.06M1.32M
Long-term debt18.9M
Total debt19.2M18.4M18.9M1.34M4.33M3.20M2.20M1.50M1.50M1.49M
Total liabilities62.9M51.8M51.1M29.3M30.3M24.2M8.97M3.95M6.56M6.93M
Shareholders' equity-37.3M1.85M24.2M44.6M84.5M81.5M73.0M109.5M38.5M20.8M
Shares outstanding20.6M15.5M13.4M13.5M14.0M13.4M9.59M8.48M6.15M5.59M

Cash flow

LineFY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016
Cash from operations-20.8M-29.2M-20.0M-21.1M-26.8M-25.9M-23.2M-28.6M-6.40M-6.02M
Capital spending-16.0K-223.0K-204.0K-5.61M-8.95M-1.50M-14.0M-21.8M-934.7K-223.2K
Free cash flow-20.8M-29.4M-20.2M-26.7M-35.8M-27.4M-37.3M-50.4M-7.34M-6.25M
Cash from investing951.0K11.2M-9.67M31.2M-20.7M-20.7M-28.1M-21.8M-934.7K-64.8K
Cash from financing11.3M15.4M-907.0K-3.27M29.6M47.2M22.0M92.3M23.7M28.0M
Dividends paid-718.0K-738.0K
Share buybacks00-278.0K-3.27M0
Change in cash-7.84M-3.62M-30.0M8.41M-18.4M3.44M-30.6M40.7M16.4M22.0M

Open Financials

Filings

FilingDateTypeFiled with
6-K · Report of a foreign issuerSep 2, 2026Current reportSEC
6-K · Report of a foreign issuerAug 14, 2026Current reportSEC
6-K · Report of a foreign issuerAug 13, 2026Current reportSEC
6-K · Report of a foreign issuerJul 15, 2026Current reportSEC
6-K · Report of a foreign issuerJun 29, 2026Current reportSEC
25-NSEJun 23, 2026Other filingsSEC
6-K · Report of a foreign issuerJun 2, 2026Current reportSEC
SCHEDULE 13D/A · Big-stake notice, amendedMay 18, 2026Big-stake noticeSEC
20-F · Annual reportMay 15, 2026Annual reportSEC
DApr 28, 2026Other filingsSEC
All 157 filings
FilingDateTypeFiled with
3 · Initial statement of ownershipApr 23, 2026Insider tradeSEC
NT 20-FApr 21, 2026Explanation requestSEC
3 · Initial statement of ownershipApr 20, 2026Insider tradeSEC
6-K · Report of a foreign issuerApr 20, 2026Current reportSEC
6-K · Report of a foreign issuerApr 20, 2026Current reportSEC
3 · Initial statement of ownershipApr 16, 2026Insider tradeSEC
6-K · Report of a foreign issuerApr 15, 2026Current reportSEC
3 · Initial statement of ownershipApr 13, 2026Insider tradeSEC
3 · Initial statement of ownershipApr 7, 2026Insider tradeSEC
3 · Initial statement of ownershipApr 3, 2026Insider tradeSEC
3 · Initial statement of ownershipApr 3, 2026Insider tradeSEC
3 · Initial statement of ownershipMar 27, 2026Insider tradeSEC
3 · Initial statement of ownershipMar 25, 2026Insider tradeSEC
SCHEDULE 13D/A · Big-stake notice, amendedMar 23, 2026Big-stake noticeSEC
3 · Initial statement of ownershipMar 18, 2026Insider tradeSEC
3 · Initial statement of ownershipMar 18, 2026Insider tradeSEC
6-K · Report of a foreign issuerMar 3, 2026Current reportSEC
DFeb 26, 2026Other filingsSEC
6-K · Report of a foreign issuerFeb 25, 2026Current reportSEC
6-K · Report of a foreign issuerFeb 20, 2026Current reportSEC
6-K · Report of a foreign issuerFeb 19, 2026Current reportSEC
SCHEDULE 13G/A · Big-stake notice, amendedFeb 17, 2026Big-stake noticeSEC
SCHEDULE 13G/A · Big-stake notice, amendedFeb 13, 2026Big-stake noticeSEC
6-K · Report of a foreign issuerFeb 10, 2026Current reportSEC
SCHEDULE 13D/A · Big-stake notice, amendedFeb 10, 2026Big-stake noticeSEC
SCHEDULE 13D/A · Big-stake notice, amendedJan 29, 2026Big-stake noticeSEC
DJan 28, 2026Other filingsSEC
DJan 28, 2026Other filingsSEC
6-K · Report of a foreign issuerJan 22, 2026Current reportSEC
SCHEDULE 13D/A · Big-stake notice, amendedJan 20, 2026Big-stake noticeSEC
SCHEDULE 13D/A · Big-stake notice, amendedJan 20, 2026Big-stake noticeSEC
6-K · Report of a foreign issuerJan 13, 2026Current reportSEC
SCHEDULE 13D/A · Big-stake notice, amendedJan 9, 2026Big-stake noticeSEC
6-K · Report of a foreign issuerDec 30, 2025Current reportSEC
6-K · Report of a foreign issuerDec 23, 2025Current reportSEC
SCHEDULE 13D/A · Big-stake notice, amendedDec 18, 2025Big-stake noticeSEC
SCHEDULE 13D/A · Big-stake notice, amendedDec 17, 2025Big-stake noticeSEC
6-K · Report of a foreign issuerDec 11, 2025Current reportSEC
SCHEDULE 13G · Big-stake noticeNov 26, 2025Big-stake noticeSEC
6-K · Report of a foreign issuerNov 19, 2025Current reportSEC
6-K · Report of a foreign issuerNov 14, 2025Current reportSEC
SCHEDULE 13G/A · Big-stake notice, amendedNov 14, 2025Big-stake noticeSEC
6-K · Report of a foreign issuerNov 10, 2025Current reportSEC
SCHEDULE 13D · Big-stake noticeSep 26, 2025Big-stake noticeSEC
6-K · Report of a foreign issuerSep 26, 2025Current reportSEC
6-K · Report of a foreign issuerSep 2, 2025Current reportSEC
6-K · Report of a foreign issuerAug 29, 2025Current reportSEC
6-K · Report of a foreign issuerAug 27, 2025Current reportSEC
SCHEDULE 13G/A · Big-stake notice, amendedAug 12, 2025Big-stake noticeSEC
6-K · Report of a foreign issuerAug 4, 2025Current reportSEC
SCHEDULE 13G/A · Big-stake notice, amendedJul 23, 2025Big-stake noticeSEC
6-K · Report of a foreign issuerJul 21, 2025Current reportSEC
SCHEDULE 13D/A · Big-stake notice, amendedJun 20, 2025Big-stake noticeSEC
6-K · Report of a foreign issuerMay 20, 2025Current reportSEC
6-K/A · Report of a foreign issuer, amendedMay 20, 2025Current reportSEC
6-K · Report of a foreign issuerMay 16, 2025Current reportSEC
6-K · Report of a foreign issuerMay 14, 2025Current reportSEC
6-K · Report of a foreign issuerMay 12, 2025Current reportSEC
6-K · Report of a foreign issuerMay 7, 2025Current reportSEC
6-K · Report of a foreign issuerApr 9, 2025Current reportSEC
6-K · Report of a foreign issuerApr 3, 2025Current reportSEC
6-K · Report of a foreign issuerApr 3, 2025Current reportSEC
424B5 · ProspectusApr 1, 2025Offer documentSEC
20-F · Annual reportMar 31, 2025Annual reportSEC
6-K · Report of a foreign issuerMar 31, 2025Current reportSEC
6-K · Report of a foreign issuerFeb 10, 2025Current reportSEC
SCHEDULE 13D/A · Big-stake notice, amendedFeb 3, 2025Big-stake noticeSEC
6-K · Report of a foreign issuerJan 21, 2025Current reportSEC
EFFECT · Notice that a registration is effectiveJan 2, 2025Other filingsSEC
CORRESP · Letter to the SECDec 30, 2024Other filingsSEC
UPLOAD · Letter from the SECDec 26, 2024Other filingsSEC
6-K · Report of a foreign issuerDec 26, 2024Current reportSEC
F-3/A · Registration statement, amendedDec 23, 2024Offer documentSEC
F-3 · Registration statementDec 20, 2024Offer documentSEC
6-K · Report of a foreign issuerDec 16, 2024Current reportSEC
6-K · Report of a foreign issuerNov 15, 2024Current reportSEC
SC 13G/A · Big-stake notice, amendedOct 29, 2024Big-stake noticeSEC
6-K · Report of a foreign issuerSep 12, 2024Current reportSEC
EFFECT · Notice that a registration is effectiveSep 4, 2024Other filingsSEC
CORRESP · Letter to the SECAug 29, 2024Other filingsSEC
F-3/A · Registration statement, amendedAug 29, 2024Offer documentSEC
UPLOAD · Letter from the SECAug 23, 2024Other filingsSEC
F-3 · Registration statementAug 16, 2024Offer documentSEC
6-K · Report of a foreign issuerAug 16, 2024Current reportSEC
S-8 · Registration statement for employee plansAug 14, 2024Offer documentSEC
SC 13D/A · Big-stake notice, amendedAug 12, 2024Big-stake noticeSEC
SC 13G · Big-stake noticeJul 25, 2024Big-stake noticeSEC
6-K · Report of a foreign issuerJul 19, 2024Current reportSEC
DJul 15, 2024Other filingsSEC
6-K · Report of a foreign issuerJul 8, 2024Current reportSEC
6-K · Report of a foreign issuerJun 27, 2024Current reportSEC
6-K · Report of a foreign issuerJun 27, 2024Current reportSEC
SC 13G · Big-stake noticeJun 20, 2024Big-stake noticeSEC
SC 13G/A · Big-stake notice, amendedJun 11, 2024Big-stake noticeSEC
UPLOAD · Letter from the SECJun 10, 2024Other filingsSEC
CORRESP · Letter to the SECMay 30, 2024Other filingsSEC
UPLOAD · Letter from the SECMay 22, 2024Other filingsSEC
6-K · Report of a foreign issuerMay 15, 2024Current reportSEC
EFFECT · Notice that a registration is effectiveMay 13, 2024Other filingsSEC
CORRESP · Letter to the SECMay 9, 2024Other filingsSEC
UPLOAD · Letter from the SECMay 8, 2024Other filingsSEC
F-3 · Registration statementMay 3, 2024Offer documentSEC
6-K · Report of a foreign issuerApr 8, 2024Current reportSEC
6-K · Report of a foreign issuerMar 28, 2024Current reportSEC
20-F · Annual reportMar 28, 2024Annual reportSEC
144 · Notice of proposed saleMar 15, 2024Other filingsSEC
6-K · Report of a foreign issuerMar 13, 2024Current reportSEC
144 · Notice of proposed saleMar 5, 2024Other filingsSEC
6-K · Report of a foreign issuerFeb 29, 2024Current reportSEC
6-K · Report of a foreign issuerFeb 9, 2024Current reportSEC
6-K · Report of a foreign issuerJan 29, 2024Current reportSEC
SC 13G/A · Big-stake notice, amendedJan 26, 2024Big-stake noticeSEC
6-K · Report of a foreign issuerDec 15, 2023Current reportSEC
6-K · Report of a foreign issuerDec 8, 2023Current reportSEC
6-K · Report of a foreign issuerNov 14, 2023Current reportSEC
SC 13G/A · Big-stake notice, amendedNov 9, 2023Big-stake noticeSEC
6-K · Report of a foreign issuerNov 8, 2023Current reportSEC
UPLOAD · Letter from the SECSep 19, 2023Other filingsSEC
CORRESP · Letter to the SECAug 25, 2023Other filingsSEC
UPLOAD · Letter from the SECAug 14, 2023Other filingsSEC
6-K · Report of a foreign issuerAug 11, 2023Current reportSEC
6-K · Report of a foreign issuerAug 1, 2023Current reportSEC
6-K · Report of a foreign issuerJul 20, 2023Current reportSEC
SC 13G/A · Big-stake notice, amendedJun 22, 2023Big-stake noticeSEC
S-8 POSMay 22, 2023Offer documentSEC
S-8 POSMay 22, 2023Offer documentSEC
S-8 POSMay 22, 2023Offer documentSEC
S-8 POSMay 22, 2023Offer documentSEC
6-K · Report of a foreign issuerMay 17, 2023Current reportSEC
6-K · Report of a foreign issuerMay 17, 2023Current reportSEC
6-K · Report of a foreign issuerApr 26, 2023Current reportSEC
20-F · Annual reportApr 26, 2023Annual reportSEC
6-K · Report of a foreign issuerApr 26, 2023Current reportSEC
SC 13D/A · Big-stake notice, amendedApr 18, 2023Big-stake noticeSEC
SC 13G · Big-stake noticeApr 10, 2023Big-stake noticeSEC
8-A12B · Registration of shares for listing on an exchangeMar 27, 2023Other filingsSEC
S-8 POSMar 21, 2023Offer documentSEC
S-8 POSMar 21, 2023Offer documentSEC
S-8 POSMar 21, 2023Offer documentSEC
S-8 POSMar 21, 2023Offer documentSEC
6-K · Report of a foreign issuerMar 21, 2023Current reportSEC
424B3 · ProspectusFeb 14, 2023Offer documentSEC
EFFECT · Notice that a registration is effectiveFeb 14, 2023Other filingsSEC
CORRESP · Letter to the SECFeb 9, 2023Other filingsSEC
F-4/AFeb 9, 2023Offer documentSEC
UPLOAD · Letter from the SECFeb 8, 2023Other filingsSEC
F-4Jan 31, 2023Offer documentSEC

Open Filings · All of its filings on SEC EDGAR

Cap table

Built by 6ix from CASI Pharmaceuticals, Inc.’s releases

Common shares
20,555,873
Fully diluted
20,555,873

Fully diluted

LineShares
Common shares20,555,873

Share count over time

CountShares
Nov 22, 202620,555,873

Open Cap table

People

6ix reads each seat by machine from the page it links to, and can misread one.

PersonSeat
James Huang
Other companies: Connect Biopharma Holdings Limited (Director · Since at least Mar 18, 2026); Atara Biotherapeutics, Inc. (Director · Since at least May 16, 2025); Orion Biotech Opportunities Corp (Chief Executive Officer, Director · May 12, 2021 – May 17, 2023 · Past); Alaunos Therapeutics, Inc. (Director · Jul 20, 2020 – Jun 6, 2023 · Past); Windtree Therapeutics, Inc. (Director · Dec 21, 2018 – Feb 22, 2023 · Past)
Director · Since at least Mar 18, 2026
Alexander A ZukiwskiGlobal Chief Medical Officer · Since at least Mar 18, 2026
Alex WuDirector · Since at least Nov 4, 2026
Chunhua WangChief Operating Officer · Since at least Mar 18, 2026
Frank SuDirector · Since at least Nov 4, 2026
Hai HuangGlobal Chief Commercial Ofcr · Since at least Mar 18, 2026
James HuangDirector · Since at least Nov 5, 2026
Junping ChenChief Medical Officer · Since at least Nov 5, 2026
Kun QianGlobal Controller · Since at least Nov 4, 2026
Thomas FolinsbeeDirector · Since at least Mar 18, 2026
All 13 people
PersonSeat
Wei GaoGeneral Counsel · Since at least Nov 5, 2026
Wei-Wu HeExecutive Chairman · Since at least Nov 5, 2026
Xuebo ZengDirector · Since at least Mar 18, 2026

Open People

Log in to ask 6ix AI your own questions about CASI Pharmaceuticals, Inc.